Michelle Arkin

Nov 17, 2024 | nature.com | Leo Gendelev |Jack Taylor |Michelle Arkin

AbstractBehavioral larval zebrafish screens leverage a high-throughput small molecule discovery format to find neuroactive molecules relevant to mammalian physiology. We screen a library of 650 central nervous system active compounds in high replicate to train deep metric learning models on zebrafish behavioral profiles. The machine learning initially exploited subtle artifacts in the phenotypic screen, necessitating a complete experimental re-run with rigorous physical well-wise randomization.

Nov 16, 2024 | flipboard.com | Leo Gendelev |Jack Taylor |Douglas Myers-Turnbull |Steven Chen |Michelle Arkin |Michael Keiser | +2 more

11 hours agoCNN — Laken Riley, 22, left home at 9:03 a.m. on February 22 with her iPhone for a February morning jog. She brought her smartwatch and noise-canceling AirPods along for the run. Just 25 minutes later, she was dead. Her house’s Ring camera footage captured Riley, wearing a ponytail and dressed in a …

May 2, 2024 | cell.com | Michelle Arkin

SummaryThe modulation of protein-protein interactions with small molecules is one of the most rapidly developing areas in drug discovery. In this review, we discuss advances over the past decade (2014–2023) focusing on molecular glues (MGs)—monovalent small molecules that induce proximity, either by stabilizing native interactions or by inducing neomorphic interactions. We include both serendipitous and rational discoveries and describe the different approaches that were used to identify them.

Jul 31, 2023 | drugtargetreview.com | Michelle Arkin

Author Bio: Michelle Arkin Michelle Arkin is a chemical biologist, Professor and Chair of Pharmaceutical Chemistry, and Director of the Small Molecule Discovery Center (SMDC) at UCSF. Michelle’s research focuses on developing methods and molecules that target currently ‘undruggable proteins,’ including protein-protein interactions and dynamic or intrinsically disordered proteins.